Cordance Medical Secures $8M Seed Funding to Enhance Brain Disease Treatment with Ultrasound Technology

Cordance Medical Secures $8M Seed Investment

Cordance Medical, based in Mountain View, California, has made headlines by announcing an oversubscribed seed financing round amounting to $8 million, a significant milestone aimed at enhancing the treatment of brain diseases using advanced noninvasive focused ultrasound technology. This funding round was led by Sonder Capital, with participation from both existing and new investors, underscoring the confidence in Cordance's innovative approach to neuro-oncology.

In addition to Sonder Capital, notable contributors included Shanda Grab Ventures, Angel Physician's Fund, SmartGateVC, and R42. Furthermore, the round was notably backed by the Sontag Foundation Innovation Fund and the Brain Tumor Investment Fund, both of which signify a strong commitment to advancing neuro-oncology care through innovative therapies.

The primary goal of this funding is to support Cordance's first-ever human clinical trial of their focused ultrasound platform, which is designed to open the blood-brain barrier (BBB) temporarily and safely. This breakthrough capability has the potential to revolutionize treatment options for brain cancer as well as other neurological conditions, allowing essential therapeutic agents to reach the brain more effectively than ever before.

Cordance's ultrasound platform sets itself apart by combining patient-specific signal processing with real-time monitoring, enabling a scalable outpatient treatment process. Impressively, this system does not require head fixation or live imaging during treatment, making it more accommodating for patients. The company has already received recognition from the FDA with a Breakthrough Device Designation in the neuro-oncology space, alongside securing a grant from the National Cancer Institute to further support their clinical trials.

According to Bhaskar Ramamurthy, PhD, Co-founder and CEO of Cordance Medical, the enthusiasm surrounding this round of investment is palpable. He expressed gratitude towards all their investors for their faith in the company’s mission. Ramamurthy highlighted the necessity of precision therapies within neurology where traditional treatment options are severely limited. The support from the NIH and investors will catalyze Cordance’s journey in delivering transformative care to patients suffering from brain disorders.

“These funds will help us realize our vision as we team up with academic collaborators and industry partners,” Ramamurthy added, emphasizing the pressing demand for innovative solutions in treating neurological diseases.

Deborah Kilpatrick, PhD, a partner at Sonder Capital, weighed in on the potential impact of focused ultrasound technology, stating, “This technology is revolutionizing treatment across multiple therapeutic areas. We believe that Cordance is poised to set new standards in neurology with a platform specifically designed for practical outpatient delivery of brain therapies.”

The potential implications of this development are significant, as targeted and effective treatments for brain disorders remain sparse. By focusing on the BBB and the dynamic nature of neuro-oncology, Cordance Medical is on a clear path to not only impact patients' lives positively but also redefine standards of care.

For more information about Cordance Medical and their groundbreaking work in the field of brain disease treatment, visit cordancemedical.com.